 |
|
Molecular targeting for treatment of advanced hepatocellular carcinoma
Korean J Hepatol. 2009;15(3):299-308. Published online 2009 Sep 30 DOI: https://doi.org/10.3350/kjhep.2009.15.3.299
|
|
Citations to this article as recorded by
 MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE
Xin Lu, Zhiyuan Chen, Wenting Mi, Jianming Zheng, Yubin Liu
Open Medicine.2024;[Epub] CrossRef Cytotoxicities of novel hydrazone compounds with pyrrolidine moiety: inhibition of mitochondrial respiration may be a possible mechanism of action for the cytotoxicity of new hydrazones
Kaan Kucukoglu, Mustafa Gul, Halise Inci Gul, Rengul Cetin-Atalay, Bernard Geny
Medicinal Chemistry Research.2018; 27(9): 2116. CrossRef Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib
Zherui Wu, Antoine Galmiche, Jin Liu, Nicolas Stadler, Dominique Wendum, Evelyne Segal-Bendirdjian, Valerie Paradis, Patricia Forgez
Cancer Letters.2017; 388: 73. CrossRef Metastatic hepatocellular carcinoma presenting as facial nerve palsy and facial pain
Jong In Yang, Jung Mook Kang, Hee Jin Byun, Go Eun Chung, Jeong Yoon Yim, Min Jung Park, Jeong-Hoon Lee, Jung Hwan Yoon, Hyo Suk Lee
The Korean Journal of Hepatology.2011; 17(4): 319. CrossRef Prognostic significance of co‐expression of nm23 and p57 protein in hepatocellular carcinoma
Hui Guo, Kejun Nan, Tinghua Hu, Jie Meng, Wentao Hui, Xiaozhan Zhang, Haixia Qin, Chenguang Sui
Hepatology Research.2010; 40(11): 1107. CrossRef Hepatocellular carcinoma – a challenge for oncologists
R. Anghel
memo - Magazine of European Medical Oncology.2010; 3(3): 97. CrossRef Current status of liver diseases in Korea: Hepatocellular carcinoma
Il Han Song, Kyung Sik Kim
The Korean Journal of Hepatology.2009; 15(Suppl 6): S50. CrossRef
|